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        Systemic autoimmunity means losing tolerance 
against ubiquitous autoantigens. Genetic factors 
are important in the pathogenesis of systemic au-
toimmunity (  1  ), e.g., genetic variants in major 
tolerance-regulator genes like FOXP3 can cause 
fatal neonatal autoimmunity in non-autoim-
mune  –  prone mice and humans (  2, 3  ). In contrast, 
the lupus erythematosus (LE) encompasses a vari-
ety of clinical manifestations, including serious 
autoimmune tissue injury that develops almost 
always after the neonatal phase (  4  ). LE rather re-
sults from a combination of variants in genes that 
control lymphoproliferation and immune regula-
tion at multiple levels (  5  ). Recently, systematic 
genome-wide studies on multiple multiethnical 
cohorts of lupus patients have identifi  ed genetic 
variants in genes like IRF5, BANK1, ITGAM, 
TNFSF4, and STAT4 by mapping genomic re-
gions associated with human systemic LE (SLE) 
(  6  –  11  ). Combinations of genetic polymorphisms 
in either weak or potent susceptibility genes seem 
to account for the variability of time of disease 
onset and clinical manifestation patterns in human 
lupus (  1, 4, 5  ). In mice, single loss-of-function 
mutations in potent susceptibility genes like Tgf-
    1, DNase1, Lyn, Fas, or C1q are suffi   cient to 
cause late-onset lupus-like autoimmunity (  12  –  18  ). 
Mutations in some susceptibility genes do not 
trigger autoimmunity in the absence of a second 
genetic factor, e.g., Sle1, Tlr7, or Tlr9 (  19  –  21  ). 
Weaker disease modifi  er genes like IL-10 or IL-
27R enhance LE only in the context of multi-
ple susceptibility genes, e.g., being provided by 
the specifi  c autoimmune genetic background 
of MRL mice (  22, 23  ). 
  Single Ig IL-1  –  related receptor (SIGIRR), 
also known as Toll  –  IL-1 receptor 8 (TIR8), is 
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  The   Sigirr   gene (also known as Tir8) encodes for an orphan receptor of the Toll-like recep-
tor (TLR)/interleukin 1 receptor family that inhibits TLR-mediated pathogen recognition in 
dendritic cells. Here, we show that   Sigirr   also inhibits the activation of dendritic cells and B 
cells upon exposure to RNA and DNA lupus autoantigens. To evaluate the functional role of 
  Sigirr   in the pathogenesis of systemic lupus erythematosus (SLE), we generated   Sigirr  -
defi  cient C57BL/6-lpr/lpr mice. These mice developed a progressive lymphoproliferative 
syndrome followed by severe autoimmune lung disease and lupus nephritis within 6 mo of 
age as compared with the minor abnormalities observed in C57BL/6-lpr/lpr mice. Lack of 
  Sigirr   was associated with enhanced activation of dendritic cells and increased expression 
of multiple proinfl  ammatory and antiapoptotic mediators. In the absence of   Sigirr  , CD4 T 
cell numbers were increased and CD4  +  CD25  +   T cell numbers were reduced. Furthermore, 
lack of   Sigirr   enhanced the activation and proliferation of B cells, including the production 
of autoantibodies against multiple nuclear lupus autoantigens. These data identify   Sigirr   as 
a novel SLE susceptibility gene in mice. 
© 2008 Lech et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months after 
the publication date (see http://www.jem.org/misc/terms.shtml). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).1880 TIR8/SIGIRR IN LUPUS   | Lech et al. 
SLE at an early age (not depicted). To avoid the impact of the 
multiple lupus susceptibility genes of the MRL genetic back-
ground, we generated   Sigirr  -defi  cient B6    lpr/lpr     mice. The auto-
immune phenotype of B6    lpr/lpr     mice is introduced only by a 
single mutated LE susceptibility gene that impairs Fas-induced 
apoptosis of autoreactive B and T cells (  12  ). B6    lpr/lpr     mice rep-
resent a rather mild model of lupus autoantibody production 
and hardly detectable autoimmune tissue injury late in life; 
therefore, B6    lpr/lpr/Tir8    /        mice could be generated without the 
problems noted with MRL    lpr/lpr/Tir8    /+     mice. For SLE pheno-
type analysis, we fi  rst evaluated the size of spleens and lymph 
nodes in 6-mo-old B6    lpr/lpr     and B6    lpr/lpr/Tir8r    /        mice. Spleens 
and lymph nodes were massively enlarged in B6    lpr/lpr/Tir8    /        
mice as compared with B6    lpr/lpr     mice (  Fig. 1 A  ).   This was 
a member of the Toll-like receptor (TLR)/IL-R family (  24  ). 
Both the extracellular and intracellular domains of SIGIRR 
diff  er from the other members of the TLR/IL-1R superfamily 
(  24  ). Its small single extracellular Ig domain does not support 
ligand binding. Furthermore, the intracellular domain of 
SIGIRR cannot activate NF-    B because it lacks two essen-
tial amino acids (Ser447 and Tyr536) in its highly conserved 
TIR domain (  24  ). SIGIRR rather acts as an endogenous in-
hibitor of TLR and IL-1 signaling because overexpression of 
SIGIRR in Jurkat or HepG2 cells substantially reduced LPS 
or IL-1  –  induced activation of NF-    B (  25  –  27  ). Pathogen 
challenge or damaging the intestinal epithelial barrier surfaces 
in mice with impaired SIGIRR function resulted in   severe 
immunity-mediated tissue damage (  25, 28  –  31  ). Lack of   Sigirr 
enhanced LPS signaling in dendritic cells and intestinal epi-
thelia. Hence, SIGIRR is one of several negative regulators 
that suppress TLR-mediated antimicrobial defense (  32  ). The 
  SIGIRR   gene is localized at the p15 region of chromosome 
11, a region to which linkage analyses have mapped yet un-
known lupus susceptibility genes (  33, 34  ). SIGIRR might 
contribute to the control of autoimmunity because SIGIRR 
suppresses TLR signaling in dendritic cells, a recently discov-
ered pathomechanism of lupus (  35  ). Immune complexes 
containing the lupus autoantigens U1snRNP or nucleosomes 
activate dendritic cells (and autoreactive B cells) in vitro via 
TLR7 and TLR9, respectively (  36  –  41  ). In vivo studies with 
TLR7 antagonists (  42  ),   Tlr7  -defi  cient mice (  43  ), or TLR7 
overexpression confi  rm this concept for TLR7 (  20, 44  ). In 
contrast, data from studies using TLR9 antagonists (  45, 46  ) 
and   Tlr9  -defi  cient autoimmune mice remain inconsistent 
(  21, 43, 47  ). 
  We hypothesized a role for SIGIRR beyond the control of 
microbial defense, namely, suppressing inadequate activation 
of antigen-presenting cells in autoimmunity. We therefore 
characterized the phenotype of   Sigirr  -defi  cient C57BL/6    lpr/lpr     
(B6    lpr/lpr    ) mice in which the   lpr   mutation causes delayed auto-
immunity and hardly detectable autoimmune tissue injury 
within 6 mo of age (  12  ). 
    RESULTS   
  Lack of Sigirr induces severe lymphoproliferation 
in B6    lpr/lpr     mice 
  To evaluate the role of SIGIRR in autoimmunity we fi  rst 
carefully evaluated   Sigirr  -defi  cient B6 mice for signs of sponta-
neous autoimmunity, e.g., autoantibodies against double-
stranded DNA (dsDNA) or rheumatoid factor. In  Sigirr  -defi  cient 
B6 mice up to 12 mo of age such antibodies could not be de-
tected (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20072642/DC1). Furthermore, no antibodies bind-
ing to   Critidae luciliae   kinetoplast DNA could be detected in 
either of the two mouse strains (not depicted), indicating that 
lack of Sigirr alone does not induce autoimmunity against 
DNA in B6 mice. Next, we backcrossed   Sigirr  -defi  cient mice 
into autoimmune MRL    lpr/lpr     mice, but we were unable to con-
tinue backcrossing beyond the F4 generation because even the 
heterozygous female MRL    lpr/lpr/Tir8    /+     died from accelerated 
    Figure 1.         Lack of Sigirr is associated with massive lymphoprolif-
eration in B6    lpr/lpr     mice.   (A and B) At 6 mo of age,   Sigirr -defi  cient B6    lpr   
mice revealed massive hyperplasia of cervical, axillar (A), and mesenteric 
lymph nodes (B) as well as splenomegaly (B). Data are means   ±   SEM 
from 12 mice in each group. *, P   <   0.05. (C) PAS staining of spleen sec-
tions indicates lymph follicle hyperplasia in   Sigirr -defi  cient B6    lpr/lpr    mice. 
Images in A and C are representative of at least 12 mice in each group. 
Bars: (B) 1 cm; (C) 100   μ  m.     JEM VOL. 205, August 4, 2008 
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cant increase of Il-12p40 production by the dendritic cells 
upon exposure to such immune complexes as well as to LPS, 
imiquimod, and CpG-DNA (  Fig. 2 A  ).   In contrast, exposure 
to U1snRNP and nucleosomes (not depicted) or to anti-
Smith (Sm) IgG (Y12) and nucleosome antibodies alone did 
not induce Il-12p40 production, respectively (  Fig. 2 A  ). Sim-
ilar results were obtained for mRNA expression levels of 
Mx1, an Ifn-      –  responsive gene, also showing that Fc recep-
tors facilitate the immunostimulatory eff  ects of RNA and 
DNA immune complexes in Ftl3 dendritic cells (  Fig. 2 B  ). 
Does Sigirr also modulate the activation of dendritic cells in 
B6    lpr/lpr     mice? We performed fl  ow cytometry to quantify and 
characterize the activation state of CD11c  +   dendritic cells 
without additional stimuli directly after the spleen harvest at 
6 mo of age. The total number of spleen CD11c  +   dendritic 
cells was signifi  cantly higher in B6    lpr/lpr/Tir8    /        mice as com-
pared with B6    lpr/lpr     mice (  Fig. 2 C  ). 50% of CD11c  +   cells 
were positive for the activation marker CD40 in B6    lpr/lpr     mice 
evident from spleen and bulk mesenteric lymph node weights 
(  Fig. 1 B  ) and from total numbers of spleen cells quantifi  ed by 
fl  ow cytometry (Fig. S1 A). Spleen histomorphology revealed 
lymph follicle hyperplasia in 6-mo-old   Sigirr  -defi  cient B6    lpr/lpr     
mice (  Fig. 1 C  ). Thus, lack of Sigirr causes excessive lympho-
proliferation in mice when introduced into the context of a 
single additional lupus susceptibility gene (  lpr  ). 
  Sigirr suppresses dendritic cell activation upon exposure 
to lupus autoantigens 
  Sigirr modulates Tlr/Il-1 signaling in dendritic cells (  25, 26  ), 
but does Sigirr also modulate the activation of dendritic cells 
upon exposure to lupus autoantigens? We prepared bone 
marrow dendritic cells from B6    lpr/lpr     and B6    lpr/lpr/Tir8    /        mice 
and exposed them either to U1snRNP or nucleosome im-
mune complexes. These classical lupus autoantigens are known 
to activate dendritic cells via Tlr7 and Tlr9 (  37, 39  ). Homo-
zygous deletion of the   Tir8   gene was associated with a signifi  -
    Figure 2.         Sigirr and dendritic cell activation.   (A and B) Dendritic cells were prepared from bone marrow cells of B6    lpr/lpr/Tir8      /     and  B6   lpr/lpr    mice and 
stimulated in vitro with various TLR agonists, including immune complexes formed by U1snRNP and the anti-U1snRNP antibody Y12 (Y12) or a nucleo-
some-specifi  c antibody and nucleosomes for 24 h. Supernatants were analyzed for IL-12p40 (A) by ELISA. MX1 mRNA levels, as a marker of type I IFN 
expression, were quantifi  ed by real-time PCR after 8 h of stimulation (B). Data are shown as mean   ±   SEM. *, P   <   0.05 versus B6    lpr/lpr/Tir8      /     mice. (C) The 
total number of CD11c  +   dendritic cells in the spleens of B6    lpr/lpr/Sigirr  /      and  B6   lpr/lpr    wild-type mice was quantifi  ed by fl  ow cytometry as described in Mate-
rials and methods. Data represent means   ±   SEM from fi  ve mice in each group. *, P   <   0.05 versus B6    lpr/lpr    mice. (D) RNA was isolated from the spleens of 
CD11b  +   cells from B6    lpr/lpr/Tir8      /     and  B6   lpr/lpr    mice for real-time PCR analysis. Data are expressed as means of the ratio of the specifi  c mRNA versus that of 
18S rRNA   ±   SEM. *, P   <   0.05 versus B6    lpr/lpr    mice. (E) Serum samples from 6-mo-old B6    lpr/lpr/Tir8      /     and  B6   lpr/lpr    mice were analyzed for IL-12p40 by ELISA. 
Data are means   ±   SEM from at least 10 mice in each group. *, P   <   0.05 versus B6    lpr/lpr    mice.   1882 TIR8/SIGIRR IN LUPUS   | Lech et al. 
with lower Foxp3 mRNA expression levels in these cells in 
B6    lpr/lpr/Tir8    /        versus B6    lpr/lpr     mice (  Fig. 3 C  ). In CD4  +  CD25        
T cells, lack of Sigirr was associated with lower mRNA 
compared with 90% in   Sigirr  -defi  cient B6    lpr/lpr     mice (  Fig. 2 C  ). 
Lack of Sigirr was also associated with increased mRNA lev-
els of Mx1, Ifn-    , and Tnf (  Fig. 2 D  ).   Sigirr  -defi  cient spleen 
dendritic cells also expressed higher levels of Baff   and Bcl2 
(  Fig. 2 D  ), which support the survival of B and/or T cells 
(  48  ). Consistent with increased dendritic cell activation 
B6    lpr/lpr/Tir8    /        mice had higher serum levels of Il-12p40 as 
compared with B6    lpr/lpr     mice (  Fig. 2 E  ). Thus, Sigirr sup-
presses dendritic cell activation upon exposure to complexed 
lupus autoantigens. 
  Sigirr suppresses CD4 T cells and maintains CD4  +  CD25  +  
T cells in B6    lpr/lpr     mice 
  How does lack of Sigirr aff  ect T cell populations in B6    lpr/lpr     
mice? The numbers of CD4  +   but not of CD8  +   T cells and 
CD4/CD8 double negative   “  autoreactive  ”   T cells were in-
creased in the spleens of   Sigirr  -defi  cient B6    lpr/lpr     mice (  Fig. 3 A  ), 
consistent with the relative percentage of these populations 
among all spleen cells (Fig. S1 B).   The total numbers and 
the percentage of splenic CD4  +  /CD25  +   T cells were reduced 
as compared with B6    lpr/lpr     mice (  Fig. 3 B   and Fig. S1 B). The 
reduced numbers of CD4  +  CD25  +   T cells were consistent 
    Figure 3.         Sigirr and T cell subsets in B6    lpr/lpr     mice.   (A and B) Flow 
cytometry was used to determine the total number of distinct T cell sub-
sets in the spleens of 6-mo-old B6    lpr/lpr/Tir8  /      and B6    lpr/lpr    mice. The histo-
gram presents means   ±   SEM of at least fi  ve mice in each group. *, P   <   
0.05 versus B6    lpr/lpr    mice. (C) Cellular mRNA was prepared from CD4  +   and 
CD4  + CD25 +   spleen cell isolates from B6    lpr/lpr/Tir8  /      and  B6   lpr/lpr    mice  and 
analyzed by real-time PCR. Data are expressed as means of the ratio of 
the specifi  c mRNA versus that of 18S rRNA   ±   SEM. *, P   <   0.05 versus 
B6    lpr/lpr    mice.   
    Figure 4.         Sigirr suppresses the proliferation of B cells from B6    lpr/lpr       
  mice.   (A) Immunostaining of spleen sections for B220 illustrates the expan-
sion of B cell areas in   Tir8 -defi  cient B6    lpr/lpr    mice. Images are representative 
of at least 12 mice in each group. (B) The total number of spleen B220  +   cells 
was quantifi  ed in B6    lpr/lpr/Tir8  /      and  B6   lpr/lpr    wild-type mice by fl  ow cytom-
etry. Data represent means   ±   SEM from fi  ve mice in each group. *, P   <   0.05 
versus B6    lpr/lpr    mice. (C) Spleen B cells from B6    lpr/lpr/Tir8  /      and  B6   lpr/lpr    mice 
were stimulated in vitro with anti-IgM antibodies, various TLR agonists, 
including immune complexes formed by U1snRNP, and the anti-U1snRNP 
antibody Y12 (Y12) or a nucleosome-specifi  c antibody and nucleosomes for 
72 h. B cell proliferation was assessed as described in Materials and meth-
ods. Data are shown as mean   ±   SEM of the OD at 490 nm. Data are shown 
as mean   ±   SEM. *, P   <   0.05 versus B6    lpr/lpr    mice. Bar: (A) 100   μ  m.    JEM VOL. 205, August 4, 2008 
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antigen recognition in B cells, we prepared CD19  +   B cells from 
B6    lpr/lpr     and B6    lpr/lpr/Tir8    /        mice and exposed them to U1snRNP 
or nucleosome immune complexes. RNA and DNA im-
mune complexes stimulated B cell proliferation just like CpG-
DNA, LPS, or imiquimod, and lack of Sigirr signifi  cantly 
increased B cell proliferation upon exposure to all of these 
TLR agonists (  Fig. 4 C  ). In contrast, anti-IgM, a Tlr-independent 
way of activating B cells, had a similar eff  ect on B cells of ei-
ther genotype. Anti-CD19 blocked the Sigirr-regulated eff  ect 
of RNA and DNA immune complexes, indicating that lupus 
immune complexes activate B cells via a CD19-dependent 
mechanism at the cell surface. In contrast, the single components 
of RNA immune complexes, i.e., U1snRNP or nucleosomes 
(not depicted) and anti-Sm IgG (Y12) or anti-nucleosomes 
(13G10) did not enhance B cell proliferation (  Fig. 4 C  ). Baff  /
BlyS and Bcl-2 B cell activation pathways may contribute to 
expression levels of the Th1 markers T-bet and Ifn-    , and the 
Th2 markers Gata and Il-4 (  Fig. 3 C  ). Collectively, Sigirr 
suppresses the expansion of CD4 T cells but maintains the 
CD4  +  CD25  +   T cell population in B6    lpr/lpr     mice. 
  Sigirr suppresses the proliferation of B cells upon exposure 
to immune complexes containing RNA or DNA 
lupus autoantigens 
  Nothing is known about the role of Sigirr in B cells. In the 
spleens of 6-mo-old   Sigirr  -defi  cient B6    lpr/lpr     mice, B220 immuno-
staining revealed an expansion of spleen B cell areas and 
an increased number of B cells was found on quantitative 
spleen cell fl  ow cytometry (  Fig. 4, A and B  ).   Immune com-
plexes containing lupus autoantigens have been reported 
to stimulate B cell proliferation via Tlr7 and Tlr9 in vitro 
(  35  –  37, 49  ). To test whether Sigirr modulates lupus auto-
    Figure 5.         Sigirr and the production of Igs and DNA autoantibodies in B6    lpr/lpr         mice.   Mice from both groups were bled at monthly intervals to 
determine serum levels of IgG (A) and dsDNA autoantibody isotypes (B) by ELISA. Serum from 6-mo-old female MRL    lpr/lpr    mice served as positive control. 
Data represent means   ±   SEM from at least 10 mice in each group. *, P   <   0.05 versus B6    lpr/lpr    mice of the same time point; #, P   <   0.05 versus month 1 of 
mice from the same strain. (C)   C. luciliae   slides were incubated with 1:50 diluted serum of 6-mo-old mice from both strains, and autoantibody binding to 
the fl  agellate  ’  s kinetoplast was detected using an FITC-labeled anti-mIgG. Signal intensity was scored applying a semiquantitative score from 0 to 3. 
Images on the left show anti-dsDNA IgG in green (top), and staining the kinetoplast DNA itself with DAPI is in blue (not depicted). The merged pictures are 
shown below demonstrating that FITC positivity matches with the kinetoplast at the fl  agella pole of   C. luciliae  . Data on the right show mean scores   ±   SEM 
from at least 6  –  10 mice in each group. *, P   <   0.05 versus B6    lpr/lpr    mice. (D) Serum levels of autoantibodies against Sm antigen, U1snRNP, nucleosomes, or 
rheumatoid factor (RF) were determined at monthly intervals by ELISA. Serum from 6-mo-old female MRL    lpr/lpr    mice served as positive control. *, P   <   0.05 
versus B6    lpr/lpr    mice of the same time point; #, P   <   0.05 versus month 1 of mice from the same strain; N.d., not done.     1884 TIR8/SIGIRR IN LUPUS   | Lech et al. 
2.3   ±   0.2 in B6    lpr/lpr     mice (P = 0.003). The observed induc-
tion of hypergammaglobulinemia and lupus autoantibodies 
in B6    lpr/lpr/Tir8    /        mice raised the question of whether these 
contribute to renal autoimmune tissue injury. Glomerular 
IgG deposits were increased in B6    lpr/lpr/Tir8    /        mice (  Fig. 6  ; 
B6    lpr     mice, 0.9   ±   0.1 vs. B6    lpr/lpr/Tir8    /        mice, 1.8   ±   0.1; P = 
0.006). Immune complex deposition mediates tissue injury 
via complement activation; hence, renal sections were also 
stained for complement factor C3c. In   Sigirr  -defi  cient B6    lpr/lpr     
mice, increased glomerular IgG deposits were associated 
with increased glomerular positivity for C3c (  Fig. 6  ; B6    lpr/lpr     
mice, 1.2   ±   0.2 vs. B6    lpr/lpr/Tir8    /        mice, 2.1   ±   0.2; P = 0.03). 
Does Sigirr also control intrarenal infl  ammation? Lack of 
Sigirr had no major impact on the mRNA expression levels 
of most of the aforementioned cytokines, chemokines, and 
transcription factors in the kidneys of B6    lpr/lpr     mice (Fig. S1). 
Collectively, Sigirr protects B6    lpr/lpr     mice not only from 
systemic autoimmunity, but also from autoimmune tissue 
injury, mainly by suppressing the activation of antigen-pre-
senting cells. 
B cell proliferation in SLE (  48  ). Baff  /BLyS mRNA levels 
in CD11b  +   cells and Bcl-2 mRNA levels were increased in 
  Sigirr  -defi  cient dendritic cells (  Fig. 2 D  ) consistent with the 
increased numbers of B cells in the spleens of   Sigirr  -defi  cient 
B6    lpr/lpr     mice (  Fig. 4 B  ). Thus, Sigirr specifi  cally suppresses the 
lupus autoantigen complex  –  induced activation and prolifera-
tion of B cells in vitro and in vivo. 
  Sigirr suppresses the production of autoantibodies 
in B6    lpr/lpr     mice 
  The role of Sigirr in modulating the activation of dendritic 
cells and B cells may aff  ect Ig production, especially the evo-
lution and production of antibodies against lupus autoanti-
gens in B6    lpr/lpr     mice. Hence, serum samples were obtained at 
monthly intervals from all mice and antibody levels were de-
termined by ELISA.   Sigirr  -defi  cient B6    lpr/lpr     mice developed 
more hypergammaglobulinemia as compared with B6    lpr     wild-
type mice, which was evident from 4 mo of age and almost 
reached the level of hypergammaglobulinemia in 6-mo-old 
female MRL    lpr/lpr     mice (  Fig. 5 A  ).   Lack of Sigirr also increased 
the production of DNA autoantibodies from IgG isotypes, 
reaching the respective levels in 6-mo-old female MRL    lpr/lpr     
mice, except that for IgG  2c   (  Fig. 5 B  ). This eff  ect antedated 
the development of hypergammaglobulinemia by 2  –  3 mo. 
The specifi  city of dsDNA autoantibodies was confi  rmed by 
using the   C. luciliae   assay. Diluted serum from B6    lpr/lpr/Tir8    /        
mice showed a much more intense binding to the dsDNA 
of the fl  agellate  ’  s kinetoplast as compared with serum of 
B6    lpr/lpr     mice (  Fig. 5 C  ). In addition, lack of Sigirr was associ-
ated with increased production of anti-Sm IgG, anti-SnRNP 
IgG, anti-nucleosome IgG, and rheumatoid factor as com-
pared with B6    lpr/lpr     mice, of which Sm antibodies and rheu-
matoid factor were already elevated from 2 mo of age (  Fig. 
5 D  ). Lack of Sigirr increased rheumatoid factor but not 
anti-Sm levels in B6    lpr/lpr     mice to the levels seen in age-
matched MRL    lpr/lpr     mice. Thus, Sigirr suppresses the pro-
duction of antibodies against numerous lupus autoantigens in 
B6    lpr/lpr     mice. 
  Sigirr protects B6    lpr/lpr     mice from autoimmune tissue injury 
  Systemic autoimmunity may or may not be associated with 
autoimmune tissue injury, which remains the ultimate defi  -
nition of SLE. Autoimmune tissue injury in murine (or 
human) SLE commonly aff  ects lungs and kidneys (  4  ). B6    lpr/lpr     
mice do not develop major autoimmune tissue lesions, al-
though mild glomerulonephritis develops at an advanced 
age in B6    lpr/lpr     mice (  12  ).   Sigirr  -defi  cient B6    lpr/lpr     mice revealed 
signifi  cant peribronchial infl  ammation characterized by mono-
nuclear cell infi  ltrates and edema (  Fig. 6  ; semiquantitative 
lung injury score for B6    lpr     mice, 0.5   ±   0.2 vs. B6    lpr/Tir8         /              
mice, 2.0   ±   0.5; P = 0.007).   Furthermore,   Sigirr   defi  ciency 
was associated with diff  use mesangio-proliferative glomeru-
lonephritis, as indicated by glomerular hypercellularity, peri-
odic acid-Schiff   (PAS)  +   matrix expansion, and glomerular 
macrophage infi  ltrates (  Fig. 6  ). The composite activity score 
for lupus nephritis was 6.8   ±   1.0 in B6    lpr/lpr/Tir8    /        mice and 
    Figure 6.         Lupus nephritis and lung injury in B6    lpr/lpr         mice.   Lung 
and renal sections were stained with PAS. On renal sections, immuno-
staining was also performed for IgG and complement factor C3c. Images 
are representative for 10 mice in each group. Bar, 200   μ  m.     JEM VOL. 205, August 4, 2008 
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factors (  1, 5  –  11, 59  ). The fi  rst two mechanisms aff  ect the loss 
of tolerance, which becomes clinically detectable by the pres-
ence of serum antinuclear antibodies. However, the presence 
of (low titers of) antinuclear antibodies in humans or in   lpr  -
defi  cient B6 mice is not generally associated with auto immune 
tissue injury (  12  ). Autoimmune tissue injury does not develop 
unless additional genetic abnormalities support the expansion 
of autoreactive lymphocytes, immune complex disease, and 
tissue pathology (  1, 5  ). Many genes have been identifi  ed that 
promote autoimmune tissue injury in complex autoimmune 
genetic backgrounds in mice (  22, 23, 59  ). However, mutant 
  Sigirr   is suffi   cient to cause a severe SLE-like lymphoprolifera-
tive syndrome and autoimmune tissue injury in B6    lpr/lpr     mice 
because Sigirr is required to, for example, suppress the activa-
tion of antigen-presenting cells that handle autoantigens (  35  ). 
We therefore conclude that   Sigirr   is a novel susceptibility gene 
for murine SLE. Interestingly, the   Sigirr   gene is localized at 
the p15.5 region of human chromosome 11, a region to 
which linkage analyses have mapped a yet unknown lupus 
susceptibility gene in African-Americans with a LOD score of 
3.3 (  34  ). Our studies propose to elucidate the role of SIGIRR 
in human SLE. 
  In summary, lack of functional Sigirr is associated with 
  severe autoimmune tissue injury in B6    lpr/lpr     mice. This repre-
sents a previously unknown function of Sigirr in autoimmunity 
control. The involvement of this as well as of other negative 
regulators in human lupus and autoimmunity in general de-
serves careful scrutiny. 
  MATERIALS AND METHODS 
  Animal studies.       Sigirr  -defi  cient mice were generated as described previ-
ously (  28  ) and backcrossed to the C57BL/6 strain (B6; Charles River Labo-
ratories) to the F6 generation. B6    lpr/lpr/Tir8    /        and B6    lpr/lpr     (Charles River 
Laboratories) were mated to generate B6    lpr/lpr/Sigirr    /+     mice, which were then 
mated among each other to generate B6    lpr/lpr/Tir8    /       , B6    lpr/lpr/Tir8    /+    , and 
B6    lpr/lpr/Tir8      +/+   mice. Littermates were used for all in vivo and in vitro experi-
mental procedures. In each individual mouse the genotype was assured by 
PCR. Mice were housed in groups of fi  ve mice in sterile fi  lter top cages with 
a 12-h dark/light cycle and unlimited access to autoclaved food and water. 
All experimental procedures were performed according to the German ani-
mal care and ethics legislation and had been approved by the local govern-
ment authorities (government of Upper Bavaria). All mice were killed by 
cervical dislocation at 24 wk of age. 
  In vitro experiments.     U1snRNP was purifi  ed from HeLa cell nuclear ex-
tracts (  60  ). The anti-Sm (B/D) antibody clone Y12, mouse IgG3 isotype, was 
purifi  ed from Y12 hybridoma supernatant (MWG Biotech). Bone marrow 
cells from wild-type and knockout mice were cultured with 20 ng/ml human 
recombinant Flt3L (R  &  D Systems) in complete medium for 7 d to generate 
  >  90% CD11c  +   dendritic cells with 40  –  50% CD11b  low  /CD86  low  /B220  high   
plasmacytoid dendritic cells and 40  –  50% CD11b  high  /B220  low   dendritic cells. 
On day 7, cells were harvested, resuspended in fresh medium, and seeded at 
4   ×   10  5   cells/well (100   μ  l/well in 96-well plates). RNAs and the isolated 
U1snRNP were preincubated with 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) cationic lipid (Carl Roth) for 30 min at room tempera-
ture. Y12 antibody was incubated with U1snRNP in PBS for 15 min on ice 
plus 5 min at 37  °  C. Stimuli were added in 100-  μ  l volume per well (20   μ  g/ml 
fi  nal concentration) of 0.5   μ  g/ml of ultrapure LPS (InvivoGen), 0.5   μ  M 
CpG-DNA 1668 (TibMolbiol), and 0.5   μ  g/ml imiquimod (Sequoia Research 
Products Ltd) for 24 h. 13G10 anti-nucleosome antibodies (BD Biosciences) 
    DISCUSSION   
  Sigirr is known to suppress antimicrobial immunity (  25  –  31  ). 
Our data identify autoimmunity control as a novel function 
of Sigirr, e.g., Sigirr inhibits the activation of dendritic cells 
upon exposure to lupus immune complexes. Such immune 
complexes contain, for example, U1snRNP or nucleosomes 
that can ligate Tlr7 and Tlr9 and activate the maturation of 
dendritic cells and B cells (  36  –  41  ). Several avenues of experi-
mental evidence support the concept that autoantigen recog-
nition via Tlr7 is another important pathomechanism for 
murine SLE, i.e., use of Tlr7 antagonists (  42  ),   Tlr7  -defi  cient 
mice (  43  ), or Tlr7 overexpression (  20, 43  ). In contrast, data 
from TLR9-defi  cient autoimmune mice revealed inconsis-
tent outcomes as compared with late onset of TLR9 antag-
onism (  43, 45  –  47  ), suggesting additional roles for TLR9 
during the early phase of autoimmunity (  35  ). B6    lpr/lpr/Tir8    /        
mice revealed enhanced activation of dendritic cells, type I 
Ifn signaling, and production of proinfl  ammatory cytokines 
like Ccl2, Il-6, and Il-12p40, and the B cell survival factors 
Baff  /BlyS and Bcl-2, which are associated with more severe 
murine and human SLE (  50  –  54  ). However, type I Ifn in-
duction was only detectable at the transcriptional level in the 
spleens of B6    lpr/lpr     mice, and we could not detect signifi  cant 
type I Ifn levels in the sera of either mouse strain. The patho-
genic role of type I Ifn varies among diff  erent murine SLE 
models (  20, 43, 47, 55  –  57  ) and has not yet been clearly de-
fi  ned in B6    lpr/lpr     mice. Sigirr also directly inhibits the prolifer-
ation of B cells upon exposure to RNA and DNA immune 
complexes, a process that also depends on the interaction 
with CD19. This fi  nding supports the concept that a surface 
receptor  –  mediated uptake of lupus immune complexes into 
intracellular endosomes precedes the Sigirr-regulated Tlr sig-
naling (  35  –  37  ). Consistent with direct and indirect Sigirr-
mediated eff  ects on B cells,   Sigirr  -defi  cient B6    lpr/lpr     mice re-
vealed increased total numbers and expansion of B cell areas 
in the spleen in association with enhanced production of lu-
pus autoantibodies. The latter eff  ect was not restricted to a 
specifi  c class of autoantibodies because lack of   Sigirr   massively 
enhanced the production of autoantibodies against multiple 
nuclear autoantigens as well as hypergammaglobulinemia. 
Regulatory T cells control autoreactive B cell populations, and 
regulatory T cells are controlled by dendritic cells via secre-
tion of Il-6 (  58  ). In fact, the induction of Il-6 in B6    lpr/lpr/Tir8    /        
mice was associated with decreased Foxp3 expression and less 
CD4  +  CD25  +   T cells in the spleens of B6    lpr/lpr/Tir8    /        mice. 
The functional eff  ect of this observation on autoreactive T 
cells remains uncertain because the CD4/CD8  –  double nega-
tive T cell population was not signifi  cantly aff  ected by the 
  Tir8   genotype. Collectively, we identifi  ed a novel function 
of the TLR/IL-1R family member Sigirr, i.e., the control of 
autoimmunity, lymphoproliferation, and autoimmune tissue 
injury mainly by inhibiting the endogenous activation of den-
dritic cells and B cells. 
  SLE results from a combination of genetic abnormal-
ities that aff  ects the handling of nuclear autoantigens, per-
sistence of autoreactive lymphocytes, and immunoregulatory 1886 TIR8/SIGIRR IN LUPUS   | Lech et al. 
  Real-time quantitative (TaqMan) RT-PCR.     Real-time RT-PCR was 
performed on total spleen mRNA as described previously (  42  ). Controls con-
sisting of ddH2O were negative for target and housekeeper genes. 300 nM of 
oligonucleotide primer and 100 nM of probes were from PE Biosystems and 
used as follows: 18S rRNA was used as a housekeeper. Controls consisting of 
ddH2O were negative for target and housekeeper genes. 300 nM of oligonucleo-
tide primer and 100 nM of probes were from Applied Biosystems and used 
as follows: IL-4: ID Mm00445259_m1 FAM 5    -ACGAAGAACACCA-
CAGAGAGTGAGC-3    ; IL-6: ID Mm00446190_m1 FAM 5    -AAATGA-
GAAAAGAGTTGTGCAATGG-3    ; IL-12: ID Mm00434165_m1 FAM 
5    -TGACATGGTGAAGACGGCCAGAGAA-3    ; Mx1: ID Mm00487796_
m1 FAM 5    -TGTACTGCTAAGTCCAAAATTAAAG-3    ; IFN-    : ID 
Mm00439546_s1 FAM: 5    -TCCACGCTGCGTTCCTGCTGTGCTT-3    ; 
IFN-    : ID Mm00801778_m1 FAM 5    -CTATTTTAACTCAAGTGGC-
ATAGAT-3    ; Tnf: ID Mm00443258_m1 FAM 5    -GTCCCCAAAGGGAT-
GAGAAGTTCCC-3    ; TLR7: ID AY035889 FAM: 5    -CCAAGAAAAT-
GATTTTAATAAC-3    ; Gata3 ID Mm00484683_m1 FAM: 5    -CCCAC-
CACGGGAGCCAGGTATGCCG-3    ; Tbx21: ID Mm00450960_m1 FAM: 
5    -GCAAGGACGGCGAATGTTCCCATTC-3    ; Ccl2: ID Mm00441242_
m1 FAM 5    -GCTCAGCCAGATGCAGTTAACGCCC-3    ; Foxp3: ID 
Mm00475156_m1 FAM 5    -ACCCAGCCACTCCAGCTCCCGGCAA-3    ; 
IL-23: ID Mm00518984_m1 FAM 5    -CAAGGACAACAGCCAGTTC-
TGCTTG-3    ; Baff   /BLyS: ID Mm00446347_m1 FAM 5    -ACTCG-
GCTGGCATCGCGAGGCTGGA-3    ; Bcl-2: ID Mm00477631_m1 FAM 
5    -GATAACGGAGGCTGGGATGCCTTTG-3    . 
  Statistical analysis.     One-way ANOVA followed by post-hoc Bonferroni  ’  s 
test was used for multiple comparisons using GraphPad Prism software 
(version 4.03). Single groups were compared by unpaired two-tailed Student  ’  s   t   
test. Data were expressed as mean   ±   SEM. Statistical signifi  cance was assumed 
at a p-value of   <  0.05. 
  Online supplemental material.     Table S1 shows production of Igs and dsDNA 
autoantibodies in B6    Tir8    /        and B6    Tir8+/+     mice. Fig. S1 shows spleen cell sub-
sets and Fig. S2 shows the mRNA expression of various genes in the kidneys of 
B6    lpr/lpr/Tir8    /        and B6   lpr/lpr/Tir8+/+    , respectively. The online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20072646/DC1. 
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